Literature DB >> 21041639

Small molecule inhibition of phosphatidylinositol-3,4,5-triphosphate (PIP3) binding to pleckstrin homology domains.

Benchun Miao1, Igor Skidan, Jinsheng Yang, Alexey Lugovskoy, Mikhail Reibarkh, Kai Long, Tres Brazell, Kulbhushan A Durugkar, Jenny Maki, C V Ramana, Brian Schaffhausen, Gerhard Wagner, Vladimir Torchilin, Junying Yuan, Alexei Degterev.   

Abstract

The PI3-kinase (PI3K) pathway regulates many cellular processes, especially cell metabolism, cell survival, and apoptosis. Phosphatidylinositol-3,4,5-trisphosphate (PIP3), the product of PI3K activity and a key signaling molecule, acts by recruiting pleckstrin-homology (PH) domain-containing proteins to cell membranes. Here, we describe a new structural class of nonphosphoinositide small molecule antagonists (PITenins, PITs) of PIP3-PH domain interactions (IC(50) ranges from 13.4 to 31 μM in PIP3/Akt PH domain binding assay). PITs inhibit interactions of a number of PIP3-binding PH domains, including those of Akt and PDK1, without affecting several PIP2-selective PH domains. As a result, PITs suppress the PI3K-PDK1-Akt pathway and trigger metabolic stress and apoptosis. A PIT-1 analog displayed significant antitumor activity in vivo, including inhibition of tumor growth and induction of apoptosis. Overall, our studies demonstrate the feasibility of developing specific small molecule antagonists of PIP3 signaling.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21041639      PMCID: PMC2993381          DOI: 10.1073/pnas.1004522107

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  31 in total

Review 1.  The phosphoinositide 3-kinase pathway.

Authors:  Lewis C Cantley
Journal:  Science       Date:  2002-05-31       Impact factor: 47.728

Review 2.  The phosphatidylinositol 3-Kinase AKT pathway in human cancer.

Authors:  Igor Vivanco; Charles L Sawyers
Journal:  Nat Rev Cancer       Date:  2002-07       Impact factor: 60.716

Review 3.  PTEN: a tumour suppressor that functions as a phospholipid phosphatase.

Authors:  T Maehama; J E Dixon
Journal:  Trends Cell Biol       Date:  1999-04       Impact factor: 20.808

4.  Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors.

Authors:  Hayato Takeuchi; Yasuko Kondo; Keishi Fujiwara; Takao Kanzawa; Hiroshi Aoki; Gordon B Mills; Seiji Kondo
Journal:  Cancer Res       Date:  2005-04-15       Impact factor: 12.701

5.  Specific inhibition of the Akt1 pleckstrin homology domain by D-3-deoxy-phosphatidyl-myo-inositol analogues.

Authors:  Emmanuelle J Meuillet; Daruka Mahadevan; Hariprasad Vankayalapati; Margareta Berggren; Ryan Williams; Amy Coon; Alan P Kozikowski; Garth Powis
Journal:  Mol Cancer Ther       Date:  2003-04       Impact factor: 6.261

Review 6.  PI3K-Akt pathway: its functions and alterations in human cancer.

Authors:  M Osaki; M Oshimura; H Ito
Journal:  Apoptosis       Date:  2004-11       Impact factor: 4.677

7.  High-resolution structure of the pleckstrin homology domain of protein kinase b/akt bound to phosphatidylinositol (3,4,5)-trisphosphate.

Authors:  Christine C Thomas; Maria Deak; Dario R Alessi; Daan M F van Aalten
Journal:  Curr Biol       Date:  2002-07-23       Impact factor: 10.834

8.  Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt.

Authors:  Lin Yang; Han C Dan; Mei Sun; Qiyuan Liu; Xia-meng Sun; Richard I Feldman; Andrew D Hamilton; Mark Polokoff; Santo V Nicosia; Meenhard Herlyn; Said M Sebti; Jin Q Cheng
Journal:  Cancer Res       Date:  2004-07-01       Impact factor: 12.701

9.  Solution structure and backbone dynamics of the pleckstrin homology domain of the human protein kinase B (PKB/Akt). Interaction with inositol phosphates.

Authors:  Daniel Auguin; Philippe Barthe; Marie-Thérèse Augé-Sénégas; Marc-Henri Stern; Masayuki Noguchi; Christian Roumestand
Journal:  J Biomol NMR       Date:  2004-02       Impact factor: 2.835

10.  PTEN mutation and epidermal growth factor receptor activation regulate vascular endothelial growth factor (VEGF) mRNA expression in human glioblastoma cells by transactivating the proximal VEGF promoter.

Authors:  Nabendu Pore; Shuang Liu; Daphne A Haas-Kogan; Donald M O'Rourke; Amit Maity
Journal:  Cancer Res       Date:  2003-01-01       Impact factor: 12.701

View more
  61 in total

1.  A HPLC method for the quantitative determination of N-(2-hydroxy-5-nitrophenylcarbamothioyl)-3,5-dimethylbenzamide in biological samples.

Authors:  Igor Skidan; Jacob Grunwald; Ritesh Thekkedath; Alexei Degterev; Vladimir Torchilin
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2011-04-06       Impact factor: 3.205

2.  Anticancer drugs: blocking phospholipid-protein interactions.

Authors:  Charlotte Harrison
Journal:  Nat Rev Drug Discov       Date:  2011-01       Impact factor: 84.694

3.  Accurate prediction of the bound form of the Akt pleckstrin homology domain using normal mode analysis to explore structural flexibility.

Authors:  Hoang T Tran; Shuxing Zhang
Journal:  J Chem Inf Model       Date:  2011-08-25       Impact factor: 4.956

4.  Targeting of Micelles and Liposomes Loaded with the Pro-Apoptotic Drug, NCL-240, into NCI/ADR-RES Cells in a 3D Spheroid Model.

Authors:  Bhushan S Pattni; Srikar G Nagelli; Bhawani Aryasomayajula; Pranali P Deshpande; Abhijit Kulkarni; William C Hartner; Ganesh Thakur; Alexei Degterev; Vladimir P Torchilin
Journal:  Pharm Res       Date:  2016-06-28       Impact factor: 4.200

5.  PI3K is involved in β1 integrin clustering by PSGL-1 and promotes β1 integrin-mediated Jurkat cell adhesion to fibronectin.

Authors:  Jixian Luo; Chunfeng Li; Tingshuang Xu; Wenai Liu; Xueqing Ba; Xiaoguang Wang; Xianlu Zeng
Journal:  Mol Cell Biochem       Date:  2014-01       Impact factor: 3.396

6.  Could the Ebola virus matrix protein VP40 be a drug target?

Authors:  Robert V Stahelin
Journal:  Expert Opin Ther Targets       Date:  2013-11-28       Impact factor: 6.902

Review 7.  Alterations and molecular targeting of the GSK-3 regulator, PI3K, in head and neck cancer.

Authors:  Michelle J Lee; Nan Jin; Jennifer R Grandis; Daniel E Johnson
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2020-02-19       Impact factor: 4.739

Review 8.  Cyclin D1, cancer progression, and opportunities in cancer treatment.

Authors:  Shuo Qie; J Alan Diehl
Journal:  J Mol Med (Berl)       Date:  2016-10-02       Impact factor: 4.599

9.  Prazosin induced lysosomal tubulation interferes with cytokinesis and the endocytic sorting of the tumour antigen CD98hc.

Authors:  Robert Fuchs; Anika Stracke; Viktoria Holzmann; Gerfried Luschin-Ebengreuth; Nathalie Meier-Allard; Nadine Ebner; Teresa Maria Lassacher; Markus Absenger-Novak; Eleonore Fröhlich; Matthias Schittmayer; Sara Cano Crespo; Manuel Palacin; Beate Rinner; Ruth Birner-Gruenberger
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2018-06-15       Impact factor: 4.739

10.  Combination Nanopreparations of a Novel Proapoptotic Drug - NCL-240, TRAIL and siRNA.

Authors:  Robert Riehle; Bhushan Pattni; Aditi Jhaveri; Abhijit Kulkarni; Ganesh Thakur; Alexei Degterev; Vladimir Torchilin
Journal:  Pharm Res       Date:  2016-03-07       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.